logo
  

Myovant Sciences Says FDA Places Phase 3 SERENE Study On Partial Clinical Hold

Myovant Sciences Ltd. (MYOV) said the Food and Drug Administration has placed a partial clinical hold on the Phase 3 SERENE study of its relugolix combination tablet proposed for the prevention of pregnancy pending amendment of the study protocol to add bone mineral density monitoring.

The FDA informed this on May 18, 2021 to the company by teleconference, Myovant said in an SEC filing dated May 19, 2021.

Myovant said it will work to implement the requested monitoring and submit the amended protocol to the FDA to resolve the issue.

On April 12, 2021, Myovant Sciences and Pfizer had announced that the first participant was dosed in the Phase 3 SERENE study. The two companies had announced a collaboration in December, 2020 to develop and commercialize relugolix.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sturtevant, Wisconsin-based BRP U.S. Inc. is recalling around 20 models of Side-by-Side vehicles citing fire risk, the U.S. Consumer Product Safety Commission. The recall involves about 34,400 units of Model Years 2020 and 2021 Can-AM Defender HD10 side-by-side vehicles. While reporting financial results for the second quarter on Friday, technology company Honeywell international Inc. (HON) raised its adjusted earnings and sales guidance for the full-year 2021, based on the second-quarter performance and management's outlook for the remainder of the year. For fiscal... Shares of Vodafone Group Plc were gaining around 2 percent in the morning trading in London after the British telecom major reported higher revenues in its first quarter. Looking ahead, the company said it is on track to deliver fiscal year 2022 guidance, with Adjusted EBITDAaL expected to be between 15.0 billion euros - 15.4 billion euros and Adjusted free cash flow of at least 5.2 billion euros
Follow RTT